Citation: A. Blumenthal and L. Morgentaler, 3CL Protease Inhibitors in Chronic Long Covid A Case Review: Effects of 3CL Protease Inhibitors Paxlovid® and Tollovid™ in a Patient with Chronic Long Covid, ResearchGate (not peer-reviewed), 2022/07/22, 10.13140/RG.2.2.23669.65766
Key Tollovid Data: We report a case of a patient with SARS-CoV-2 infection and persistent Long Covid symptoms for over 2 years, who received the therapeutic intervention Paxlovid®. After finding no relief using Paxlovid®, the subject initiated supplementation with the 3CL protease inhibitor immune support dietary supplement Tollovid™. Within 30 days of using Tollovid™, the subject’s neutralizing antibodies levels increased by 30% and the subject reported being at 80% of her pre-COVID baseline health.